Researchers have used CRISPR to switch back on a gene that vanished from the human lineage roughly 20 million years ago, reviving a natural defense against excess uric acid that our ancestors once relied on. By restoring this ancient uricase enzyme in liver cells, they are pointing toward a future in which gout, fatty liver disease, kidney damage and even some cardiovascular risks could be tackled at their metabolic roots rather than managed piecemeal with lifelong drugs.
The work sits at the intersection of evolutionary biology and precision medicine, using a modern gene editing toolkit to reinstall a molecular safeguard that most other mammals never lost. It is an early stage, lab based advance, but it hints at a new class of therapies that do not just treat symptoms, they reinstall protective systems that human evolution traded away.
Why humans lost a crucial uric acid shield
To understand why reviving this gene matters, I first need to look at what was lost. Most mammals carry a working uricase enzyme that breaks down uric acid before it can accumulate, but genetic mutations in human ancestors silenced this uricase gene millions of years ago, leaving people with much higher baseline uric acid levels than other animals. As a result, uric acid now routinely forms in the blood and can crystallize in joints and kidneys, a vulnerability that underpins gout, kidney disease and a range of metabolic problems that modern medicine struggles to keep in check, as highlighted in reporting on how reactivating a long lost uricase gene changes that chemistry.
Evolutionary biologists have argued that this loss once conferred an advantage, because higher uric acid helped early primates store energy from fruit sugars during long periods without food, a tradeoff that made sense in a world of scarcity but looks far more dangerous in an era of abundant calories. As diets have shifted toward processed foods and sugary drinks, the same uric acid that once buffered starvation now fuels gout flares, kidney stones and fatty deposits in the liver, a pattern that researchers describe when they trace how the ancient uricase gene once protected against uric acid buildup related to fruit sugars in work summarized on gene loss and modern disease.
Gout, fatty liver and the burden of high uric acid
The clinical stakes of that evolutionary quirk are painfully clear. Gout is an ancient form of arthritis caused by the buildup of sharp uric acid crystals in joints, which triggers intense swelling, redness and often excruciating pain in places like the big toe, ankle or knee. Those same crystals can also form in the kidneys, contributing to kidney disease and compounding the damage from hypertension and diabetes, a cascade that researchers describe when they explain how gout and several other health issues are tied to chronic uric acid overload.
High uric acid does not stop at joints and kidneys. It is closely linked to fatty liver disease, a condition in which fat accumulates in liver cells and can progress to inflammation, scarring and eventually liver failure, especially in people who also struggle with obesity and insulin resistance. About a quarter to half of patients with high blood pressure also have elevated uric acid, and in new hypertension cases that overlap is even more striking, a convergence that Georgia State scientists emphasize as they describe how gout, fatty liver disease and hypertension cluster around the same metabolic fault line.
How CRISPR resurrected a 20 million year old gene
The new work uses CRISPR not to knock out a harmful gene, but to reinstall a protective one that humans once had. Researchers have successfully resurrected a 20 million year old uricase gene by inserting it into the genomes of human liver cells, using CRISPR to place the sequence in a safe harbor region where it can be expressed without disrupting other vital functions. In the lab, those edited cells began producing a working uricase enzyme that broke down uric acid efficiently, a proof of concept that is detailed in coverage of how scientists revive a 20 million year old gene and route the resulting protein to the right parts of the cell.
Instead of relying on repeated infusions of synthetic uricase, which can provoke immune reactions and lose effectiveness over time, the CRISPR strategy aims to turn liver cells into a permanent factory for the enzyme. A CRISPR method that restores uricase directly in liver cells could avoid those issues by integrating the gene into the genome and letting the body regulate its production, a strategy that researchers describe when they explain how CRISPR brings back an ancient gene that other animals continue to carry.
Inside the Georgia State experiment
The most detailed glimpse of this approach so far comes from a team at Georgia State University that focused on the liver, the body’s main hub for uric acid metabolism. In a study that revived the ancient uricase gene, the scientists used CRISPR Cas9 to insert a functional version of the gene into liver cells, restoring an enzyme most animals still have and that humans lost, and then tracked how those edited cells handled uric acid compared with unedited controls, as described in their report on reviving the ancient gene to target gout and fatty liver disease.
When the revived gene was active, uric acid levels dropped and markers of fatty liver improved, suggesting that the restored uricase was not only present but metabolically effective. The team framed this as a potential way to treat both gout and fatty liver disease at once, rather than addressing them as separate conditions, and they linked the benefits to the same evolutionary story in which human ancestors lost uricase while other animals retained it, a narrative that is echoed in coverage of how Researchers Restore Ancient Gene to Fight High Uric Acid and Fatty Liver using CRISPR Cas9 Technology.
What makes CRISPR suited to this kind of gene revival
CRISPR has already transformed genetic medicine by making it possible to cut and edit DNA with unprecedented precision, but this project shows how it can also be used to reintroduce entire genes that evolution has erased. In the new study, researchers used CRISPR gene editing to insert the ancient uricase gene into the genomes of human liver cells, carefully choosing a location that would allow the gene to be switched on without interfering with other critical sequences, a technical feat that is spelled out in descriptions of how CRISPR inserts the ancient uricase gene into human liver cells.
Because CRISPR Cas9 can be programmed to target specific DNA sequences, it lets scientists design edits that mimic what the human genome might look like if the uricase gene had never been lost, effectively rolling back a single evolutionary change without touching the rest of the genome. Researchers at Georgia State and collaborating institutions describe how they used this flexibility to restore the gene in a way that could be scaled up, presenting their work as a template for other projects in which CRISPR Technology lets Researchers bring back protective genes that once shielded humans from metabolic stress.
Potential benefits for patients with gout and fatty liver disease
If this approach can be translated safely into people, the payoff could be substantial for patients who now cycle through medications that only partially control their disease. Current gout treatments often focus on lowering uric acid production or increasing its excretion, but they can cause side effects and do not always prevent flares, especially in patients with kidney problems or complex metabolic profiles. By contrast, a therapy that restores uricase in the liver could continuously break down uric acid before it crystallizes, a prospect that scientists highlight when they describe how reviving an ancient human gene could help cure gout and reduce the risk of several other health issues linked to uric acid overload, as outlined in coverage of Scientists Revive an Ancient Human Gene that could help cure gout.
Fatty liver disease, which is notoriously difficult to treat once it progresses, could also benefit from a more fundamental reset of uric acid metabolism. In experimental models, restoring uricase not only lowered uric acid but also improved markers of liver fat and inflammation, suggesting that the enzyme’s activity reverberates through broader metabolic pathways. That is why researchers argue that a CRISPR based uricase therapy would be a useful tool for treating gout and fatty liver diseases together, a dual benefit that is emphasized in reports on how treating gout and fatty liver diseases with a revived gene could change the standard of care.
How this work fits into the broader CRISPR revolution
The uricase project is part of a wider wave of CRISPR research that is moving from rare genetic disorders into common chronic diseases. CRISPR has already been used to treat conditions like sickle cell disease by editing blood stem cells, but targeting a metabolic pathway that affects gout, fatty liver disease and hypertension signals a shift toward diseases that affect tens of millions of people. Reports on this latest work describe how CRISPR Researchers Have Resurrected An Ancient Gene That Can Prevent Disease, framing it as an example of how Researchers Have Resurrected An Ancient Gene That Can Prevent Disease and potentially improve the quality of life for patients with chronic metabolic conditions.
What makes this work stand out is its explicitly evolutionary angle, using CRISPR not just to correct rare mutations but to revisit big genetic decisions that shaped the human species. Instead of asking how to fix a broken gene, the researchers asked whether it is possible to reinstall a gene that human ancestors discarded, and whether doing so would be safe and beneficial in a modern environment. That conceptual leap is why some commentators see the project as a harbinger of a new era in which CRISPR Researchers Have Resurrected An Ancient Gene That Can Prevent Disease and may eventually apply similar strategies to other lost protective traits.
Risks, unknowns and ethical questions
For all its promise, reviving an ancient gene in humans is not a trivial step, and the risks are still being mapped out. Uric acid, for example, is not purely harmful, it also acts as an antioxidant in the blood, and lowering it too far could have unintended consequences for immune function or brain health. Scientists involved in the work acknowledge that the original loss of uricase may have been advantageous in a world of scarce food, and they caution that any therapy that reintroduces the enzyme will need to be carefully tuned so it does not overshoot and create new vulnerabilities, a balance that is implicit in analyses of why it was less advantageous to have uricase when long periods without food were common.
There are also broader ethical questions about how far medicine should go in rewriting evolutionary history. Editing liver cells in adults to restore uricase is very different from editing embryos, but it still raises questions about long term safety, access and the possibility of off target effects that might not appear for years. Regulators will have to weigh those concerns against the heavy burden of gout, fatty liver disease and kidney damage, conditions that already shorten lives and strain health systems, and they will need robust data from trials that build on the early lab work described in reports on how reactivating a long lost uricase gene changes uric acid dynamics in controlled settings.
From lab bench to clinic: what comes next
Translating this gene revival from petri dishes to patients will require a series of careful steps, starting with animal studies that test safety, dosing and delivery methods. Researchers are exploring viral vectors and lipid nanoparticles to ferry the CRISPR components into liver cells, and they will need to show that the edits are precise, durable and do not trigger dangerous immune responses. The early work suggests that a CRISPR method that restores uricase directly in liver cells could avoid some of the issues seen with injected enzyme therapies, a point that is underscored in descriptions of how CRISPR brings back ancient gene based uricase in the liver.
If those preclinical studies are successful, early phase human trials would likely focus on patients with severe, treatment resistant gout or advanced fatty liver disease, where the potential benefits are greatest and the risks of inaction are high. Over time, if safety and efficacy hold up, the therapy could move earlier in the disease course, perhaps even as a preventive option for people with very high uric acid and a strong family history of gout or metabolic syndrome. For now, the work stands as a striking example of how CRISPR is maturing from a gene editing concept into a platform for reengineering human biology, using insights from evolution to guide interventions that could reshape how we think about chronic disease.
More from MorningOverview